Sign Up to like & get
recommendations!
1
Published in 2019 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2018.11.022
Abstract: Immunotherapy with the use of immune checkpoint inhibitors has emerged as a new pillar in cancer therapeutics. Nivolumab is an antibody targeting programmed cell death 1 (PD-1) signaling, which is approved for urothelial cancer treatment…
read more here.
Keywords:
immune checkpoint;
related nivolumab;
urothelial cancer;
case ... See more keywords